Mobidiag provides innovative solutions for in vitro diagnostics of infectious diseases. More reliable and faster diagnostics can ensure patient care and safety by detecting infection type allowing selection of the appropriate treatment with or without antibiotics. Mobidiag has used its expertise in the detection of gastrointestinal infections and multi-drug resistant organisms, also known as superbugs. Product lines currently available are well suited for high-throughput laboratories. Upcoming products are instrument and test cassettes that detect simultaneously panels of bacteria, viruses or parasites. This syndromic approach brings effective DNA technique closer to patients in a user-friendly and economically effective format reducing overall healthcare costs and directing better patient treatment.
Mobidiag now invests strongly to expand its sales and marketing channels in
This new funding will allow Mobidiag to finalize and scale up its product manufacturing and assay validation, as well as to strengthen its sales and marketing activities.
Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo,
Mobidiag addresses both high to medium volume screening with the Amplidiag® Easy platform, bringing the Amplidiag® suite further by automating the workflow from sample to results, and the upcoming Novodiag® platform & associated panels for a fully automated solution and suitable for smaller volumes and labs. For more information, visit www.mobidiag.com
Established in 2012,